Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
2.
Case Rep Pulmonol ; 2014: 368780, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24653848

RESUMEN

Sarcoidosis and Crohn's disease are systemic granulomatous disorders affecting the lung and the intestine, respectively, with variable involvement of other organs and are seldom associated. While anti-TNF α is a recognized treatment of Crohn's disease, its usage is discussed in sarcoidosis. A 42-year-old man presented with an 11-year-long history of Crohn's disease; upon discovery of an abnormal chest CT scan the diagnosis of multivisceral sarcoidosis was made and, later, a treatment with an anti-TNF α agent, infliximab, was started, because of worsening Crohn's disease recurrences. CT scan demonstrated net regression of pulmonary opacities and hepatosplenic lesions. Pathologies obtained from the intestinal tract and the bronchi of the patient were, respectively, characteristic of Crohn's disease and sarcoidosis leading to the diagnosis of both diseases. We report a rare case of steroid resistant Crohn's disease associated with multivisceral sarcoidosis, treated successfully by an anti-TNF α agent, infliximab.

4.
Rare Tumors ; 5(3): e32, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24179644

RESUMEN

Urachal adenocarcinoma is a rare neoplasm of the bladder. Most of these tumors arise from urachal remnants in the dome of the bladder and extend into the umbilicus. These tumors can recur and most commonly metastasize to lymph nodes, retroperitoneum, lungs, liver and bone. Here we report a case of an urachal adenocarcinoma followed for seven years with lung metastasis for three years.

5.
Bull Cancer ; 99(11): 1077-81, 2012 Nov.
Artículo en Francés | MEDLINE | ID: mdl-23113992

RESUMEN

Surgery is the standard treatment of early-stage non-small cell lung cancer (NSCLC). However, all patients do not undergo radical resection because of the very frequent co-morbidities occurring in smokers. Recently, new therapeutic options have emerged for limited-size (less than 4 cm) NSCLC tumors. Stereotactic radiotherapy consists of the use of multiple radiation micro-beams, allowing high doses of radiation to be delivered to the tumor in a small number of fractions. Radiofrequency ablation delivers high frequency electromagnetic waves through a needle-like probe, that produces ionic agitation, increase of the temperature in the tumor tissue, and ultimately leads to coagulation necrosis of the tumor. Several studies have been reported, that show the efficacy of these treatment modalities to control stage I/II NSCLC in medically inoperable patients. Local control rates are consistently reported to be above 90 %. Stereotactic radiation therapy and radiofrequency ablation are now being evaluated prospectively; namely, stereotactic radiotherapy is being compared to surgery in operable patients in several randomized trials. Overall, from a technical concept to the availability of specific treatment devices and the publication of clinical results, stereotactic radiotherapy and radiofrequency ablation are paradigms of implementation in thoracic oncology.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/cirugía , Ablación por Catéter/métodos , Detección Precoz del Cáncer , Neoplasias Pulmonares/cirugía , Radiocirugia/métodos , Carcinoma de Pulmón de Células no Pequeñas/patología , Fraccionamiento de la Dosis de Radiación , Humanos , Neoplasias Pulmonares/patología , Estadificación de Neoplasias , Carga Tumoral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA